Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: A mesenteric mass surrounded by fibrosis is a hallmark feature of small intestinal neuroendocrine tumors (SI-NETs) that can induce severe abdominal complications. To improve clinical outcome, there is a need for personalized treatment strategies based on accurate prediction of development of abdominal complications.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Blazevic A
Authors: Blazevic A, Starman M, Brabander T, Hofland J, Franssen G,
Keywords: Small-intestinal neuroendocrine tumors, mesenteric mass, mesenteric fibrosis, radiomics, CT scan,
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Bodei L
Authors: Bodei L, Kidd M, Singh A, van der Zwan W, Severi S,
Keywords: biomarker, PRRT, prediction, NETest, PPQ, CgA, personalized medicine,
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: van der Zwan W
Authors: Van der Zwan W, Brabander T, Kam B, Teunissen J, Krenning E,
Keywords: Salvage, PRRT, Re-treatment, GEP-NET, Safety, Efficacy, 177Lu-DOTATATE,
#2216 Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker
Introduction: We have developed a blood-based tool (gene expression analysis and tumor grade) for predicting PRRT efficacy.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Bodei L
Authors: Bodei L, Kidd M, van der Zwan W, Singh A, Severi S,
Keywords: Biomarker, carcinoid, PRRT, prediction, therapy, efficacy, stratification,
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Delea T, Rotter J, Wang X,
Keywords: neuroendocrine tumors, clinical trials, overall survival, progression-free survival, meta-analysis,